Last edition
News about "Sandoz for Pertuzumab Biosimilar"
EirGenix Signs Second Global Licensing Deal With Sandoz for Pertuzumab Biosimilar
EirGenix Inc., a Taiwan-based biopharmaceutical and CDMO company, has signed a second global exclusive licensing agreement with Sandoz AG for the commercialization of its pertuzumab biosimilar EG1206A, developed as an alternative to Roche’s Perjeta.
Sandoz For Pertuzumab Biosimilar | 14/11/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members